help button home button Endocrine Society Molecular Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Culig, Z.
Right arrow Articles by Klocker, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Culig, Z.
Right arrow Articles by Klocker, H.

Molecular Endocrinology, Vol 7, 1541-1550, Copyright © 1993 by Endocrine Society

ARTICLES

Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone

Z Culig, A Hobisch, MV Cronauer, AC Cato, A Hittmair, C Radmayr, J Eberle, G Bartsch and H Klocker
Department of Urology, University of Innsbruck, Austria.

Structural changes of the androgen receptor (AR) may contribute to the development of resistance to endocrine therapy in prostatic carcinoma. We have isolated AR cDNA fragments from seven tumor specimens derived from patients with advanced metastatic prostatic tumors. In one specimen obtained from a patient who failed to respond to endocrine and cytotoxic therapy we have detected a point mutation in the hormone- binding domain of the receptor. This AR mutation is a guanine-to- adenine transition at nucleotide 2671 that leads to substitution of methionine for the wild type valine at position 715. It is a somatic mutation because it was not present in the AR genomic DNA fragments isolated from prostatic and testicular tissues of the same patient. The mutant AR was recreated in an expression vector and transiently expressed in COS-7 and CV-1 cells. Hormone-binding assays revealed that the mutant receptor does not differ from the wild type receptor in its ability to bind androgen. The dissociation constant for the synthetic androgen mibolerone was 3 nM for both receptors. There was also no significant difference in binding of other steroids and nonsteroidal antiandrogens as revealed by competition binding assays. However, transfection experiments to determine the trans-activation potential of the mutant receptor produced differences in the action of this receptor compared to the wild type receptor. Dihydrotestosterone and the synthetic androgens methyltrienolone (R1881) and mibolerone were equally proficient in conferring trans-activation activity to both the mutant and wild type receptors. Adrenal androgens such as dehydroepiandrosterone and androstenedione, as well as progesterone mediated a higher trans-activation through the mutant than through the wild type receptor. These data demonstrate that the exchange of a single valine into methionine at position 715 in the AR promoters trans- activation not only by testicular but also by adrenal androgens and progesterone. This pattern of ligand-dependent trans-activation may have significance in the process controlling the progression of prostatic carcinoma.


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
B. Wegiel, A. Bjartell, J. Tuomela, N. Dizeyi, M. Tinzl, L. Helczynski, E. Nilsson, L. E. Otterbein, P. Harkonen, and J. L. Persson
Multiple Cellular Mechanisms Related to Cyclin A1 in Prostate Cancer Invasion and Metastasis
J Natl Cancer Inst, July 16, 2008; 100(14): 1022 - 1036.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. C. Hodgson, I. Astapova, A. N. Hollenberg, and S. P. Balk
Activity of Androgen Receptor Antagonist Bicalutamide in Prostate Cancer Cells Is Independent of NCoR and SMRT Corepressors
Cancer Res., September 1, 2007; 67(17): 8388 - 8395.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. J. Ryan, S. Halabi, S.-S. Ou, N. J. Vogelzang, P. Kantoff, E. J. Small, and for the Cancer and Leukemia Group B
Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study
Clin. Cancer Res., April 1, 2007; 13(7): 2030 - 2037.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Z. Yang, Y.-J. Chang, H. Miyamoto, S. Yeh, J. L. Yao, P. A. di Sant'Agnese, M.-Y. Tsai, and C. Chang
Suppression of Androgen Receptor Transactivation and Prostate Cancer Cell Growth by Heterogeneous Nuclear Ribonucleoprotein A1 via Interaction with Androgen Receptor Coregulator ARA54
Endocrinology, March 1, 2007; 148(3): 1340 - 1349.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
D. A. Benitez, E. Pozo-Guisado, A. Alvarez-Barrientos, P. M. Fernandez-Salguero, and E. A. Castellon
Mechanisms Involved in Resveratrol-Induced Apoptosis and Cell Cycle Arrest in Prostate Cancer-Derived Cell Lines
J Androl, March 1, 2007; 28(2): 282 - 293.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
Z. Yang, Y.-J. Chang, H. Miyamoto, J. Ni, Y. Niu, Z. Chen, Y.-L. Chen, J. L. Yao, P. A. di Sant'Agnese, and C. Chang
Transgelin Functions as a Suppressor via Inhibition of ARA54-Enhanced Androgen Receptor Transactivation and Prostate Cancer Cell Growth
Mol. Endocrinol., February 1, 2007; 21(2): 343 - 358.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. N. Davis, K. J. Wojno, S. Daignault, M. D. Hofer, R. Kuefer, M. A. Rubin, and M. L. Day
Elevated E2F1 Inhibits Transcription of the Androgen Receptor in Metastatic Hormone-Resistant Prostate Cancer
Cancer Res., December 15, 2006; 66(24): 11897 - 11906.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. B. Wetherill, J. K. Hess-Wilson, C. E.S. Comstock, S. A. Shah, C. R. Buncher, L. Sallans, P. A. Limbach, S. Schwemberger, G. F. Babcock, and K. E. Knudsen
Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer
Mol. Cancer Ther., December 1, 2006; 5(12): 3181 - 3190.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
X. Yuan, T. Li, H. Wang, T. Zhang, M. Barua, R. A. Borgesi, G. J. Bubley, M. L. Lu, and S. P. Balk
Androgen Receptor Remains Critical for Cell-Cycle Progression in Androgen-Independent CWR22 Prostate Cancer Cells
Am. J. Pathol., August 1, 2006; 169(2): 682 - 696.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
H. Le, J. T. Arnold, K. K. McFann, and M. R. Blackman
DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells
Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E952 - E960.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. He, R. T. Gampe Jr., A. T. Hnat, J. L. Faggart, J. T. Minges, F. S. French, and E. M. Wilson
Probing the Functional Link between Androgen Receptor Coactivator and Ligand-binding Sites in Prostate Cancer and Androgen Insensitivity
J. Biol. Chem., March 10, 2006; 281(10): 6648 - 6663.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. T. Arnold and M. R. Blackman
Does DHEA Exert Direct Effects on Androgen and Estrogen Receptors, and Does It Promote or Prevent Prostate Cancer?
Endocrinology, November 1, 2005; 146(11): 4565 - 4567.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Yoshida, H. Kinoshita, T. Segawa, E. Nakamura, T. Inoue, Y. Shimizu, T. Kamoto, and O. Ogawa
Antiandrogen Bicalutamide Promotes Tumor Growth in a Novel Androgen-Dependent Prostate Cancer Xenograft Model Derived from a Bicalutamide-Treated Patient
Cancer Res., November 1, 2005; 65(21): 9611 - 9616.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Z Culig, H Steiner, G Bartsch, and A Hobisch
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. T. Arnold, H. Le, K. K. McFann, and M. R. Blackman
Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells
Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E573 - E584.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. C. Hodgson, I. Astapova, S. Cheng, L. J. Lee, M. C. Verhoeven, E. Choi, S. P. Balk, and A. N. Hollenberg
The Androgen Receptor Recruits Nuclear Receptor CoRepressor (N-CoR) in the Presence of Mifepristone via Its N and C Termini Revealing a Novel Molecular Mechanism for Androgen Receptor Antagonists
J. Biol. Chem., February 25, 2005; 280(8): 6511 - 6519.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. B. Wetherill, N. L. Fisher, A. Staubach, M. Danielsen, R. W. de Vere White, and K. E. Knudsen
Xenoestrogen Action in Prostate Cancer: Pleiotropic Effects Dependent on Androgen Receptor Status
Cancer Res., January 1, 2005; 65(1): 54 - 65.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. A. Heinlein and C. Chang
Androgen Receptor in Prostate Cancer
Endocr. Rev., April 1, 2004; 25(2): 276 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Rahman, H. Miyamoto, and C. Chang
Androgen Receptor Coregulators in Prostate Cancer: Mechanisms and Clinical Implications
Clin. Cancer Res., April 1, 2004; 10(7): 2208 - 2219.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. W. Gregory, X. Fei, L. A. Ponguta, B. He, H. M. Bill, F. S. French, and E. M. Wilson
Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer
J. Biol. Chem., February 20, 2004; 279(8): 7119 - 7130.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Mohler, C. W. Gregory, O. H. Ford III, D. Kim, C. M. Weaver, P. Petrusz, E. M. Wilson, and F. S. French
The Androgen Axis in Recurrent Prostate Cancer
Clin. Cancer Res., January 15, 2004; 10(2): 440 - 448.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. K. Lee and C. Chang
Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4043 - 4054.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
W. G. Nelson, A. M. De Marzo, and W. B. Isaacs
Prostate Cancer
N. Engl. J. Med., July 24, 2003; 349(4): 366 - 381.
[Full Text] [PDF]

Home page
 JCOHome page
M.-E. Taplin, B. Rajeshkumar, S. Halabi, C. P. Werner, B. A. Woda, J. Picus, W. Stadler, D. F. Hayes, P. W. Kantoff, N. J. Vogelzang, et al.
Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663
J. Clin. Oncol., July 15, 2003; 21(14): 2673 - 2678.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. M. Rahman, H. Miyamoto, H. Takatera, S. Yeh, S. Altuwaijri, and C. Chang
Reducing the Agonist Activity of Antiandrogens by a Dominant-negative Androgen Receptor Coregulator ARA70 in Prostate Cancer Cells
J. Biol. Chem., May 23, 2003; 278(22): 19619 - 19626.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. M. Rahman, H. Miyamoto, H. Lardy, and C. Chang
Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells
PNAS, April 29, 2003; 100(9): 5124 - 5129.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Miyamoto, P. Marwah, A. Marwah, H. Lardy, and C. Chang
3beta -Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity
PNAS, April 15, 2003; 100(8): 4440 - 4444.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
D. J. Lamb, E. Puxeddu, N. Malik, D. L. Stenoien, R. Nigam, G. Y. Saleh, M. Mancini, N. L. Weigel, and M. Marcelli
Molecular Analysis of the Androgen Receptor in Ten Prostate Cancer Specimens Obtained Before and After Androgen Ablation
J Androl, March 1, 2003; 24(2): 215 - 225.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Hara, J.-i. Miyazaki, H. Araki, M. Yamaoka, N. Kanzaki, M. Kusaka, and M. Miyamoto
Novel Mutations of Androgen Receptor: A Possible Mechanism of Bicalutamide Withdrawal Syndrome
Cancer Res., January 1, 2003; 63(1): 149 - 153.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B. Comuzzi, L. Lambrinidis, H. Rogatsch, S. Godoy-Tundidor, N. Knezevic, I. Krhen, Z. Marekovic, G. Bartsch, H. Klocker, A. Hobisch, et al.
The Transcriptional Co-Activator cAMP Response Element-Binding Protein-Binding Protein Is Expressed in Prostate Cancer and Enhances Androgen- and Anti-Androgen-Induced Androgen Receptor Function
Am. J. Pathol., January 1, 2003; 162(1): 233 - 241.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Masiello, S. Cheng, G. J. Bubley, M. L. Lu, and S. P. Balk
Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor
J. Biol. Chem., July 12, 2002; 277(29): 26321 - 26326.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. V. Krishnan, X.-Y. Zhao, S. Swami, L. Brive, D. M. Peehl, K. R. Ely, and D. Feldman
A Glucocorticoid-Responsive Mutant Androgen Receptor Exhibits Unique Ligand Specificity: Therapeutic Implications for Androgen-Independent Prostate Cancer
Endocrinology, May 1, 2002; 143(5): 1889 - 1900.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Neckers
Heat Shock Protein 90 Inhibition by 17-Allylamino-17- demethoxygeldanamycin: A Novel Therapeutic Approach for Treating Hormone-refractory Prostate Cancer : Commentary re: D. B. Solit et al., 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and Her-2/neu and Inhibits the Growth of Prostate Cancer Xenografts. Clin. Cancer Res., 8: 986-993, 2002.
Clin. Cancer Res., May 1, 2002; 8(5): 962 - 966.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. B. Wetherill, C. E. Petre, K. R. Monk, A. Puga, and K. E. Knudsen
The Xenoestrogen Bisphenol A Induces Inappropriate Androgen Receptor Activation and Mitogenesis in Prostatic Adenocarcinoma Cells
Mol. Cancer Ther., May 1, 2002; 1(7): 515 - 524.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. Zou, W. Zhang, D. Young, M. G. Gleave, P. Rennie, T. Connell, R. Connelly, J. Moul, S. Srivastava, and I. Sesterhenn
Maspin Expression Profile in Human Prostate Cancer (CaP) and in Vitro Induction of Maspin Expression by Androgen Ablation
Clin. Cancer Res., May 1, 2002; 8(5): 1172 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C.-Y. Chang and D. P. McDonnell
Evaluation of Ligand-Dependent Changes in AR Structure Using Peptide Probes
Mol. Endocrinol., April 1, 2002; 16(4): 647 - 660.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X.-B. Shi, A.-H. Ma, L. Xia, H.-J. Kung, and R. W. de Vere White
Functional Analysis of 44 Mutant Androgen Receptors from Human Prostate Cancer
Cancer Res., March 1, 2002; 62(5): 1496 - 1502.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. L. Zegarra-Moro, L. J. Schmidt, H. Huang, and D. J. Tindall
Disruption of Androgen Receptor Function Inhibits Proliferation of Androgen-refractory Prostate Cancer Cells
Cancer Res., February 1, 2002; 62(4): 1008 - 1013.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Stanbrough, I. Leav, P. W. L. Kwan, G. J. Bubley, and S. P. Balk
Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium
PNAS, September 4, 2001; (2001) 191235898.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. E. Taplin and S.-M. Ho
The Endocrinology of Prostate Cancer
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477.
[Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. Thompson, F. Saatcioglu, O. A. Janne, and J. J. Palvimo
Disrupted Amino- and Carboxyl-Terminal Interactions of the Androgen Receptor Are Linked to Androgen Insensitivity
Mol. Endocrinol., June 1, 2001; 15(6): 923 - 935.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Buchanan, N. M. Greenberg, H. I. Scher, J. M. Harris, V. R. Marshall, and W. D. Tilley
Collocation of Androgen Receptor Gene Mutations in Prostate Cancer
Clin. Cancer Res., May 1, 2001; 7(5): 1273 - 1281.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
G. Buchanan, M. Yang, J. M. Harris, H. S. Nahm, G. Han, N. Moore, J. M. Bentel, R. J. Matusik, D. J. Horsfall, V. R. Marshall, et al.
Mutations at the Boundary of the Hinge and Ligand Binding Domain of the Androgen Receptor Confer Increased Transactivation Function
Mol. Endocrinol., January 1, 2001; 15(1): 46 - 56.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
S. Signoretti, R. Montironi, J. Manola, A. Altimari, C. Tam, G. Bubley, S. Balk, G. Thomas, I. Kaplan, L. Hlatky, et al.
Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer
J Natl Cancer Inst, December 6, 2000; 92(23): 1918 - 1925.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. W. Hsing, Y.-T. Gao, G. Wu, X. Wang, J. Deng, Y.-L. Chen, I. A. Sesterhenn, F. K. Mostofi, J. Benichou, and C. Chang
Polymorphic CAG and GGN Repeat Lengths in the Androgen Receptor Gene and Prostate Cancer Risk: A Population-based Case-Control Study in China
Cancer Res., September 1, 2000; 60(18): 5111 - 5116.
[Abstract] [Full Text]

Home page
 J. Cell Biol.Home page
M. Becker, E. Martin, J. Schneikert, H. F. Krug, and A. C.B. Cato
Cytoplasmic Localization and the Choice of Ligand Determine Aggregate Formation by Androgen Receptor with Amplified Polyglutamine Stretch
J. Cell Biol., April 17, 2000; 149(2): 255 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Marcelli, M. Ittmann, S. Mariani, R. Sutherland, R. Nigam, L. Murthy, Y. Zhao, D. DiConcini, E. Puxeddu, A. Esen, et al.
Androgen Receptor Mutations in Prostate Cancer
Cancer Res., February 1, 2000; 60(4): 944 - 949.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
L. V. Nazareth, D. L. Stenoien, W. E. Bingman III, A. J. James, C. Wu, Y. Zhang, D. P. Edwards, M. Mancini, M. Marcelli, D. J. Lamb, et al.
A C619Y Mutation in the Human Androgen Receptor Causes Inactivation and Mislocalization of the Receptor with Concomitant Sequestration of SRC-1 (Steroid Receptor Coactivator 1)
Mol. Endocrinol., December 1, 1999; 13(12): 2065 - 2075.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
B. B. Yeap, R. G. Krueger, and P. J. Leedman
Differential Posttranscriptional Regulation of Androgen Receptor Gene Expression by Androgen in Prostate and Breast Cancer Cells
Endocrinology, July 1, 1999; 140(7): 3282 - 3291.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
M.-E. Taplin, G. J. Bubley, Y.-J. Ko, E. J. Small, M. Upton, B. Rajeshkumar, and S. P. Balk
Selection for Androgen Receptor Mutations in Prostate Cancers Treated with Androgen Antagonist
Cancer Res., June 1, 1999; 59(11): 2511 - 2515.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken
Molecular Genetics and Epidemiology of Prostate Carcinoma
Endocr. Rev., February 1, 1999; 20(1): 22 - 45.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
C. Lopez-Otin and E. P. Diamandis
Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features
Endocr. Rev., August 1, 1998; 19(4): 365 - 396.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P.-M. Holterhus, H. T. Bruggenwirth, O. Hiort, A. Kleinkauf-Houcken, K. Kruse, G. H. G. Sinnecker, and A. O. Brinkmann
Mosaicism due to a Somatic Mutation of the Androgen Receptor Gene Determines Phenotype in Androgen Insensitivity Syndrome
J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3584 - 3589.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J.-a. Tan, Y. Sharief, K. G. Hamil, C. W. Gregory, D.-Y. Zang, M. Sar, P. H. Gumerlock, R. W. deVere White, T. G. Pretlow, S. E. Harris, et al.
Dehydroepiandrosterone Activates Mutant Androgen Receptors Expressed in the Androgen-Dependent Human Prostate Cancer Xenograft CWR22 and LNCaP Cells
Mol. Endocrinol., April 1, 1997; 11(4): 450 - 459.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
E. T. Keller, C. Chang, and W. B. Ershler
Inhibition of NFkappa B Activity through Maintenance of Ikappa Balpha Levels Contributes to Dihydrotestosterone-mediated Repression of the Interleukin-6 Promoter
J. Biol. Chem., October 18, 1996; 271(42): 26267 - 26275.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. J. Bubley and S. P. Balk
Treatment of Androgen-Independent Prostate Cancer
Oncologist, February 1, 1996; 1(1): 30 - 35.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M.-E. Taplin, G. J. Bubley, T. D. Shuster, M. E. Frantz, A. E. Spooner, G. K. Ogata, H. N. Keer, and S. P. Balk
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
N. Engl. J. Med., May 25, 1995; 332(21): 1393 - 1398.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. D. Wilson
The Promiscuous Receptor -- Prostate Cancer Comes of Age
N. Engl. J. Med., May 25, 1995; 332(21): 1440 - 1441.
[Full Text]

Home page
 J. Biol. Chem.Home page
F. Yeung, X. Li, J. Ellett, J. Trapman, C. Kao, and L. W. K. Chung
Regions of Prostate-specific Antigen (PSA) Promoter Confer Androgen-independent Expression of PSA in Prostate Cancer Cells
J. Biol. Chem., December 22, 2000; 275(52): 40846 - 40855.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Han, B. A. Foster, S. Mistry, G. Buchanan, J. M. Harris, W. D. Tilley, and N. M. Greenberg
Hormone Status Selects for Spontaneous Somatic Androgen Receptor Variants That Demonstrate Specific Ligand and Cofactor Dependent Activities in Autochthonous Prostate Cancer
J. Biol. Chem., March 30, 2001; 276(14): 11204 - 11213.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Stanbrough, I. Leav, P. W. L. Kwan, G. J. Bubley, and S. P. Balk
Prostatic